Clinical diagnostic performance of light‐initiated chemiluminescent assay compared with the Architect chemiluminescence immunoassay for detection of HCV antibody. Issue 7 (30th May 2019)
- Record Type:
- Journal Article
- Title:
- Clinical diagnostic performance of light‐initiated chemiluminescent assay compared with the Architect chemiluminescence immunoassay for detection of HCV antibody. Issue 7 (30th May 2019)
- Main Title:
- Clinical diagnostic performance of light‐initiated chemiluminescent assay compared with the Architect chemiluminescence immunoassay for detection of HCV antibody
- Authors:
- Yang, Shuo
Yang, Ruifeng
Zhang, Siyu
Liu, Di
Zhou, Jiansuo
Wang, Tiancheng
Cui, Liyan - Abstract:
- Abstract: Background: Hepatitis C virus antibody (anti‐HCV) test had been approved as a preliminary screening test for HCV infection. Light‐initiated chemiluminescent assay (LiCA) was a homogenous method. We aimed to assess the clinical diagnostic performance of LiCA and compare it with that of chemiluminescence immunoassay (CLIA) which was widely used in clinical laboratories. Methods: A total of 10 772 patients from the Peking University Third Hospital were enrolled. The serum samples were detected on the ChIVD LiCA500 and Abbott Architect i2000SR platforms. Recombinant immunoblot assay (RIBA) and HCV RNA assay were used for confirmation. Results: The negative agreement rate between ChIVD LiCA anti‐HCV assay and Abbott Architect anti‐HCV assay was 99.91%, the positive agreement rate was 37.31%, the total agreement rate was 98.74%, and the kappa coefficient (κ) was 0.519. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ChIVD LiCA anti‐HCV assay were 96.39%, 99.95%, 89.58%, and 99.97%, respectively, which were superior to those of Abbott Architect anti‐HCV assay (93.98%, 99.25%, 51.90%, and 99.95%, respectively). Conclusion: ChIVD LiCA anti‐HCV assay was a highly sensitive, specific homogenous method with good diagnostic performance, and was applicable for the routine screening of HCV infection in clinical laboratories.
- Is Part Of:
- Journal of clinical laboratory analysis. Volume 33:Issue 7(2019)
- Journal:
- Journal of clinical laboratory analysis
- Issue:
- Volume 33:Issue 7(2019)
- Issue Display:
- Volume 33, Issue 7 (2019)
- Year:
- 2019
- Volume:
- 33
- Issue:
- 7
- Issue Sort Value:
- 2019-0033-0007-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2019-05-30
- Subjects:
- Abbott Architect anti‐HCV assay -- ChIVD LiCA 500 analyzer -- HCV antibody -- HCV RNA -- hepatitis C -- recombinant immunoblot assay
Diagnosis, Laboratory -- Periodicals
Medical laboratory technology -- Periodicals
616 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/jcla.22928 ↗
- Languages:
- English
- ISSNs:
- 0887-8013
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4958.520000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 11783.xml